---
document_datetime: 2025-12-18 16:11:57
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/afqlir-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: afqlir-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.6964545
conversion_datetime: 2026-01-03 12:55:32.100946
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Afqlir

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 18/12/2025                          |                                             | SmPC and                         |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000314162                     | PRODUCTS - C.I.z Other variation - Accepted C.I.z - to update sections 2, 4.2, 6.5 of the SmPC and sections 2, 4 and 5 of the Labelling sections of the PL to adapt the amount of aflibercept in mg specified in the Afqlir vial prescribing information. In addition, the MAH took the opportunity to update section 4.2 of the SmPC for the Afqlir PFS prescribing information. Finally, the contact details of the local representative for Denmark, Norway, Sweden and Slovenia were updated.   |            |     | Labelling   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type IA / EMA/VR/0000316742 | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted                                                                                                                                                                                                                               | 16/12/2025 | N/A |             |
| Variation type IB / EMA/VR/0000295239 | B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re- test period/storage period supported by real time data - Accepted                                                                                                                                                                                                                                                                                                                                          | 24/09/2025 | N/A |             |
| Variation type IB / EMA/VR/0000275018 | B.I.e.5 Implementation of changes foreseen in an approved change management protocol - B.I.e.5.c Implementation of a change for a biological/immunological                                                                                                                                                                                                                                                                                                                                          | 23/07/2025 |     | Annex II    |

<div style=\"page-break-after: always\"></div>

|                                        | medicinal product - Accepted                                                                                                                                                                                                                                                                                                                                                 |            |     |             |    |
|----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|----|
| Variation type IB / EMA/VR/0000279285  | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted                                                                                                                                                      | 16/07/2025 |     | SmPC and PL |    |
| Variation type IA_IN EMA/VR/0000279769 | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted                                                                                                                                                                                               | 17/06/2025 | N/A |             | /  |
| Variation type IB / EMA/VR/0000264282  | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z Other variation - Accepted | 04/06/2025 | N/A |             |    |
| Variation type II / EMA/VR/0000254901  | B.II.g) Design Space and post approval change management protocol - B.II.g.2 Introduction of a post approval change management protocol related to the finished product - Accepted                                                                                                                                                                                           | 08/05/2025 | N/A |             |    |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000262726   | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted   | 28/04/2025   | N/A   |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000263912   | B.II.c.2 Change in test procedure for an excipient - B.II.c.2.d Other changes to a test procedure (including replacement or addition) - Accepted                                                                                                                                                                                                                                                                                                                                                                  | 28/04/2025   | N/A   |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Variation type IB / EMA/VR/0000263394   | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update section 4.8 of the SmPC                                                                                                                                  | 24/04/2025   |       | SmPC and PL | To update section 4.8 of the SmPC in order to add 'scleritis' to the list of adverse drug reactions (ADRs) with a frequency of '0.2 cases per 1 million injections' based on pharmacovigilance data. The Package Leaflet is updated accordingly. The MAH also took the opportunity to add warnings for polysorbate into the SmPC and the Package Leaflet in line with the instructions in the most recent updates to the Appendix of the EC Excipient Guideline, and made an editorial correction to |

<div style=\"page-break-after: always\"></div>

|                                       | in order to add 'scleritis' to the list of adverse drug reactions (ADRs) with a frequency of '0.2 cases per 1 million injections' based on pharmacovigilance data, following the same change of the reference product. The Package Leaflet is updated accordingly. The MAH also took the opportunity to add warnings for polysorbate into the SmPC and the Package Leaflet in line with the instructions in the most recent updates to the Appendix of the EC Excipient Guideline, and made an editorial correction to section 4.8 of the SmPC in ES language to include a previously missing table 1 description, in alignment with the reference product. In addition, the MAH took the opportunity to update the contact information of the local representative of   |            |     | section 4.8 of the SmPC in ES language to include a previously missing table 1 description, in alignment with the reference product.   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000262014 | B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.b Addition of a new test(s) and limits - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 14/04/2025 | N/A |                                                                                                                                        |
| Variation type IA / EMA/VR/0000255758 | B.II.c.2 Change in test procedure for an excipient - B.II.c.2.a Minor changes to an approved test procedure - Refused                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 21/03/2025 | N/A |                                                                                                                                        |
| Variation type IA / EMA/VR/0000256533 | B.II.b.5 Change to in-process tests or limits applied during the manufacture of the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 05/03/2025 | N/A |                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| finished product - B.II.b.5.z Minor change of an analytical procedure for an in-process control - Accepted   |
|--------------------------------------------------------------------------------------------------------------|